Boost ROI by targeting minimally invasive BPH devices, outpatient care and Asia-Pacific expansion while investing in innovation, physician training and strategic partnerships.Dublin, Oct. 13, 2026 ...
BPH prostate treatment market is evolving toward a more patient-focused, technology-driven ecosystem. As innovation in both pharmaceuticals and minimally invasive procedures accelerates, companies ...
Butterfly Medical, developer of a proprietary minimally invasive solution for benign prostatic hyperplasia (BPH), today announced that it has received certification under the European Union Medical ...
Butterfly Medical, developer of a minimally invasive solution for benign prostatic hyperplasia (BPH), has earned EU MDR ...
TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...
Harnessing Real-World Data and AI to Advance Research and Treatment for Benign Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...
Teleflex Incorporated announced the presentation of multiple clinical studies at the 2025 American Urological Association Annual Meeting in Las Vegas, highlighting advancements in treatments for ...
Latest FDA Approvals, Clinical Trials, And Emerging Therapies Assessment By Delveinsight. (Albany, US), October 23, ...
HistoSonics reported the successful treatment of the first patients in WOLVERINE, a new trial evaluating the Edison Histotripsy System for benign prostatic hyperplasia (BPH). The treatments come about ...
Introduction: Do not endure frequent urinationWaking up multiple times at night to use the toilet, weak urine flow, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results